'Antibody drug conjugate' presentation slideshows

The oncology field is witnessing rapid growth, owing to emergence of novel therapies with high efficacy, which in turn is boosting growth of the oncology drug pipeline market. For instance, in 2015, the U.S. Food and Drug Administration (U.S FDA) approved 45 New Molecular Entity (NME) and new Biologic License Applications (BLA), of which 16 were novel cancer therapies. Therefore, developments of novel drugs is a major factor propelling growth of the Global Oncology Drug Pipeline Analysis Market.

49 views • 4 slides

Oncology Drug Pipeline Analysis Market Rising Trends and Demands In Healthcare Industry 2018-2026

The oncology field is witnessing rapid growth, owing to emergence of novel therapies with high efficacy, which in turn is boosting growth of the oncology drug pipeline market. For instance, in 2015, the U.S. Food and Drug Administration (U.S FDA) approved 45 New Molecular Entity (NME) and new Biologic License Applications (BLA), of which 16 were novel cancer therapies.

50 views • 4 slides

Antibody drug conjugate is a significant class of highly potent bio drugs envisioned as a broad therapy for treatment of cancer.

51 views • 3 slides